Innovation Pharmaceuticals Inc (IPIX)

[midwestice]

What are your thoughts on how a valuation would be done? Primary end point was not met in Covid trial, secondary endpoints pending, compassionate use ongoing for COVID. Then there are the expanded results both reported and ongoing trials for a variety of viruses, which may point to broad spectrum antiviral capability. In addition, there is the Brilacidin for OM treatment angle which is an ongoing trial for what appears to be an unmet need in that niche. Kevetrin may add value separately. However, even with all the promise surrounding the pipeline some uncertainty remains. I guess I'm curious what the typical process is to assign a realistic value in scenarios like this. I've been trying to educate myself, but am still in the learning process...